drugset
drugset / Trial / NCT04086121

A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032

NCT04086121 ↗

Phase 2 Terminated 14 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

To assess the long term safety and efficacy of treatment with BI 655130 in patients with AD who have completed and have responded to treatment in the parent study 1368-0032

Timeline

Start
2019-09-24
Primary completion
2021-04-28
Completion
2022-02-23

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision”

Drugs

EvaluationDrugModalityDoseRoute
Subject Spesolimab Monoclonal antibody 600 mg Subcutaneous

Indications

atopic eczema